Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
Globe Newswire•05/11/2026•16:02 ET
0
Key Highlights
- ➤Kyverna management will present at Jefferies Global Healthcare Conference November 19, 2026
- ➤Miv-cel received three FDA RMAT designations across neurologic autoimmune diseases
- ➤Kyverna completed its registrational stiff person syndrome trial
- ➤Registrational generalized myasthenia gravis trial remains ongoing
EMERYVILLE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the Jefferies Global Healthcare Conference in London, United Kingdom on Thursday, November 19, 2026, at 10:00 am GMT.
A live webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on the website for approximately 90 days following the conference.
Get started
Create a free account to read the full story.